# Early Mortality and Mid-Term Durability of Open Surgical Repair for Complex Abdominal Aortic Aneurysms in Octogenarians: A Retrospective Analysis from Two Tertiary Referral Centers

Francesco Andreoli, Alexandre Azoulay, Ludovic Canaud, Pierre Alric, Paul Girardet, Pietro Federico Ricciardi, Ludovica Ettorre, Jacopo Galafassi, Daniel Schmauss, Luca Giovannacci, et al.

► To cite this version:

Francesco Andreoli, Alexandre Azoulay, Ludovic Canaud, Pierre Alric, Paul Girardet, et al. Early Mortality and Mid-Term Durability of Open Surgical Repair for Complex Abdominal Aortic Aneurysms in Octogenarians: A Retrospective Analysis from Two Tertiary Referral Centers. Journal of Clinical Medicine, 2025, 14 (19), pp.6983. 10.3390/jcm14196983. hal-05319005

HAL Id: hal-05319005

https://hal.science/hal-05319005v1

Submitted on 17 Nov 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Early Mortality and Mid-Term Durability of Open Surgical Repair for Complex Abdominal Aortic Aneurysms in Octogenarians: A Retrospective Analysis from Two Tertiary Referral Centers

Francesco Andreoli<sup>1</sup>, Alexandre Azoulay<sup>2</sup>, Ludovic Canaud<sup>2 3</sup>, Pierre Alric<sup>2 3</sup>, Paul Girardet<sup>2 4</sup>, Pietro Federico Ricciardi<sup>1</sup>, Ludovica Ettorre<sup>1</sup>, Jacopo Galafassi<sup>1</sup>, Daniel Schmauss<sup>5 6</sup>, Luca Giovannacci<sup>1</sup>, Alessandro Robaldo<sup>1</sup>, Giorgio Prouse<sup>1</sup>

<sup>1</sup> Division of Vascular Surgery and Angiology, Centro Vascolare Ticino, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.

<sup>2</sup> Department of Vascular and Thoracic Surgery, University of Montpellier, CHU Montpellier, 34090 Montpellier, France.

<sup>3</sup> PhyMedExp, University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Montpellier, 34090 Montpellier, France.

<sup>4</sup> Department of Vascular and Endovascular Surgery, Hôpital Louis Pradel, Hospices civils de Lyon, 69500 Bron, France.

<sup>5</sup> Department of Plastic and Reconstructive Surgery, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.

<sup>6</sup> Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.

## Keywords:

cardiovascular adverse events; complex aortic aneurysms; mid-term survival; octogenarians; open aortic surgery; peri-operative mortality; postoperative complications.
# Abstract

**Background/Objectives:**

Complex endovascular solutions have expanded treatment options for complex abdominal aortic aneurysms (cAAA), particularly in elderly high-risk patients. However, these techniques are limited by anatomical constraints and costs, while the superiority over open repair (OSR) remains debatable. This study aimed to compare short- and mid-term outcomes of OSR for cAAA in patients aged ≥80 versus <80 years.

**Methods:**

Retrospective analysis was performed for patients who underwent OSR for cAAA between 2017 and 2022 at two tertiary vascular centers. A total of 226 patients (median age 71 years [IQR 66-80]; 89% male) were included, of whom 74 were aged ≥80 years. Primary endpoints were 30-day mortality, major adverse cardiovascular events (MACE), and early reintervention. Secondary endpoints included length of stay (LOS), acute kidney injury, new renal dysfunction, mid-term survival (≤5 years), and procedure-related reintervention. Propensity score matching (PSM) was performed to adjust for baseline differences.

**Results:**

Out of 1087 screened patients, 226 met the inclusion criteria: 74 octogenarians and 152 younger patients. Thirty-day mortality was significantly higher in octogenarians (9.5% vs. 0.7%; *p* < 0.001), as was the incidence of MACE (8.2% vs. 1.9%; *p* = 0.026). Rates of kidney impairment LOS and other major complications were comparable. During a median follow-up of 42.7 months, mid-term survival and freedom from reintervention did not differ significantly between groups. PSM analysis confirmed higher early mortality and cardiovascular events in octogenarians but similar mid-term outcomes.

**Conclusions:**

Although octogenarians undergoing OSR for cAAA face increased early mortality and cardiovascular complications, their mid-term survival and freedom from reintervention are comparable to younger patients. These results suggest that age alone should not represent a contraindication to open repair in appropriately selected individuals.
# 1. Introduction

Fenestrated (fEVAR) and branched (bEVAR) endovascular techniques have expanded treatment options for complex abdominal aortic aneurysms (cAAA), offering a less invasive alternative to open surgical repair (OSR), especially in elderly or high-risk patients [1–5]. These approaches enable treatment of juxtarenal (jAAA) and pararenal (pAAA) aneurysms while preserving renal and mesenteric perfusion. Their minimally invasive nature—avoiding aortic clamping and reducing hemodynamic and metabolic stress—helps lower postoperative complications and mortality [3,6,7]. Accordingly, f/bEVAR have become the preferred option in many centers when anatomically feasible, particularly for elderly patients [8–21]. However, f/bEVAR remain limited by technical complexity and anatomical constraints, with outcomes worsening when used outside the instructions for use [1,22–25]. Additionally, some evidence indicates higher mortality rates in octogenarians compared with younger patients [26–29]. Moreover, these procedures are unsuitable for emergencies, impose substantial logistical and financial burdens, and are associated with a high rate of reintervention at both 3 and 5 years [6,30–32]. Although 30-day outcomes of fEVAR/bEVAR in older patients are generally favorable, robust comparative evidence between OSR and f/bEVAR remains limited, as many studies are confounded by variability in patient characteristics and institutional practices [5,13,18,33,34]. Whether age alone should preclude OSR remains uncertain [35–37]. Data on outcomes in octogenarians are limited, and the assumption that elderly patients cannot tolerate OSR may not apply to those with good functional status [33,34]. To address this issue, we compared outcomes of patients ≥ 80 vs. <80 years undergoing open repair for cAAA. A propensity score-matched analysis was performed to assess the impact of age on short- and mid-term mortality and morbidity, aiming to support informed clinical decision-making in this complex population.

# 2. Materials and Methods

## 2.1. Study Design and Patients' Population

A retrospective analysis was performed on over one thousand consecutive open abdominal aortic aneurysm (AAA) repairs conducted between January 2017 and 2022 at two tertiary-level vascular referral centers. Data specific to juxtarenal and pararenal abdominal aortic aneurysms were extracted from a prospectively maintained database and included in the current study cohort. Exclusion criteria were patients under 18 years of age, those with ruptured AAAs, and individuals who underwent surgery for infrarenal AAAs, suprarenal AAA, thoracoabdominal aneurysms, aortic dissections, conversions to open repair following failed endovascular treatment, or any form of hybrid repair. The final study population was stratified into two groups: Group I included patients aged ≥80 years (octogenarian group), and Group II included those aged <80 years (non-octogenarian group).

All patients were discussed at multidisciplinary vascular meetings, which had different structures at the two centers. Both teams included vascular surgeons and angiologists; however, at one of the centers, an interventional radiologist was also required to be present at every meeting. Aneurysmal characteristics were determined by review of computed tomography angiography scans and radiology reports. Patients were selected for treatment based on the following criteria: maximum aneurysm diameter > 55 mm in men or >50 mm in women, or documented aneurysm growth > 1 cm per year; life expectancy > 5 years; and a
left ventricular ejection fraction ≥ 40% on resting transthoracic echocardiography. Stress tests were performed only in one of the participating centers for patients deemed fit for testing. In all other cases stress myocardial scintigraphy was used to assess inducible myocardial ischemia. Other criteria included functional capacity estimation > 4 metabolic equivalent [38] and no active incidental malignancy found during investigations. Preoperative assessment included pulmonary function testing and referral for specialist evaluation when indicated, except for patients undergoing a retroperitoneal approach at one of the centers, where pulmonary evaluation was performed only in those with chronic obstructive pulmonary disease. Patients with an ASA score of 4 were proposed for open surgery if an endovascular solution was contraindicated or sub-optimal.

Comorbidities, intraoperative variables, adverse events, and follow-up data were prospectively recorded in an intra-center registry at one site and in a national registry at the other. These data were retrospectively analyzed for the purposes of this study. All surviving patients were sent a non-opposition consent form, except those recruited from one of the two centers where, since 2021, all participants have provided signed informed consent for clinical research and data analysis.

The study was approved by the local Ethics Committee (2024-00501 CE 4561). Helsinki Declaration and its later amendments were respected and the data underlying this article will be shared on reasonable request to the corresponding author.

## 2.2. Surgical Procedure

All procedures were performed or directly supervised by a senior vascular surgeon with ≥10 years post specialty experience. General anesthesia was administered in all cases, with epidural analgesia employed when feasible. The choice between a transperitoneal or retroperitoneal approach was determined based on the operating surgeon's preference or patient-specific anatomical and clinical considerations. A blood salvage system was routinely used. Renal cold perfusion with 0.9% saline at 4 °C was employed in all cases requiring renal artery reimplantation or bypass revascularization and selectively according to anatomical situation and surgeon's preference in all cases of juxtarenal anastomosis. Division of the left renal vein was generally avoided; however, when necessary, it was reconstructed in all instances. In one of the two centers, systemic renal protection with intravenous mannitol (0.5 mg/kg) was routinely administered approximately 20 min prior to suprarenal aortic clamping. Systemic anticoagulation was achieved with intravenous sodium heparin (50–70 U/kg) prior to clamping, and the aortic cross-clamp was positioned at the inter-renal, suprarenal, or— when dictated by specific anatomical constraints—above the superior mesenteric artery or celiac trunk. Additional heparin dosing was guided by activated clotting time measurements. In patients with a pAAA, once the proximal anastomosis was completed, one or both renal arteries were revascularized either by direct reimplantation or by short aorto-renal bypass grafts, depending on anatomic feasibility and surgeon preference. At both centers, reimplantation of the inferior mesenteric artery was routinely performed when the vessel was patent and considered suitable in diameter and quality by the senior surgeon.
**2.3. Standard Post Operative Care**

All patients received standardized postoperative care in the intensive care unit for the first
night or longer, as clinically needed. Oral intake was resumed following the return of bowel
function evidenced by the passage of flatus. Early mobilization was initiated within 24 h
postoperatively whenever feasible. In one center, the nasogastric drainage tube was routinely
removed immediately following surgery, whereas in the other center, it was routinely retained
for the first 24 postoperative hours, subsequently removed once biliary drainage was minimal
or absent. Additionally, all patients underwent early respiratory physiotherapy (within 12 h
from surgery when feasible) to reduce pulmonary complications.

**2.4. Definitions and Outcomes**

Baseline characteristics, including demographics, comorbidities, and intraoperative details, were recorded. Chronic heart failure was classified according to contemporary ESC and AHA/ACC/HFSA guidelines [39], and chronic kidney disease (CKD) was defined as an eGFR < 60 mL/min/1.73 m2 or dialysis, staged by KDIGO criteria [40]. Renal ischemia time was reported as total (aortic clamp to reperfusion of the last renal artery) and partial (aortic clamp to reperfusion of the ☐rst renal artery). Adjunctive procedures were any intraoperative interventions not directly related to aneurysm repair or renal revascularization.

Primary outcomes were 30-day mortality, major adverse cardiovascular events (MACE: persistent hemodynamically relevant arrhythmia, heart failure (HF), myocardial infarction, or stroke), and early reintervention (<30 days). Secondary outcomes included length of hospital stay (LOS), acute kidney injury (AKI, KDIGO criteria) [41], new-onset renal dysfunction (eGFR < 60 mL/min/1.73 m2 at 30 days), minor complications, mid-term survival (≤5 years), and procedure-related reintervention. Pulmonary complications were defined as pneumonia, ventilatory support > 48 h, or unplanned reintubation. HF was defined as any structural or functional impairment of ventricular filling or ejection of blood, leading to manifestations of dyspnea, fatigue, and fluid retention.

Visceral impairment referred to clinically significant non-bowel organ dysfunction (e.g., liver failure, pancreatitis). Postoperative kidney impairment was a persistent reduction in eGFR < 60 mL/min/1.73 m2 without AKI in patients with normal baseline function. Major adverse events (MAEs) comprised MACE, pulmonary complications, bowel ischemia, acute limb or spinal cord ischemia, visceral impairment, AKI, postoperative kidney impairment, and hemorrhagic complications.

**2.5. Statistical Analysis**

Categorical variables were reported as frequencies and percentages. The distribution of
continuous variables was assessed using the Shapiro-Wilk test. Normally distributed variables
were presented as mean ± standard deviation and compared with the independent samples t-
test; non-normally distributed variables were presented as median [IQR] and compared using
the Wilcoxon-Mann-Whitney U test. Categorical comparisons were performed using the χ2
test or Fisher's exact test when expected cell counts were <5. Kaplan-Meier curves were
generated to estimate survival and freedom from reintervention during follow-up, with group
comparisons performed using the log-rank test. Univariate analyses were conducted to assess
differences between groups for baseline characteristics and outcomes. Continuous secondary
outcomes (e.g., length of stay) and continuous variables with significant intergroup
differences (e.g., total and partial renal ischemic times, intraoperative blood loss) were
dichotomized at the median for regression analyses. Univariable and multivariable logistic
regression models were used to identify predictors of MACE, 30-day mortality, and early
reintervention. Variables with p < 0.20 in univariable analysis were entered into the
multivariable model using stepwise forward selection. Model fit was evaluated using the
Akaike information criterion and Pearson χ² goodness-of-fit test.

To reduce potential confounding from differences between the two centers, propensity score matching (PSM) was performed using a 1:1 nearest-neighbor algorithm with a caliper of 0.01. Propensity scores were estimated from preoperative demographic, clinical, and intraoperative variables. Post-matching balance was assessed by re-comparing baseline characteristics between groups. All statistical tests were two-sided, with p < 0.05 considered statistically significant. Analyses were performed using STATA version 18 (StataCorp, College Station, TX, USA).

3. Results

**3.1. Baseline Characteristics**

Of 226 patients meeting the inclusion criteria (Figure 1), 74 (32.7%)were aged ≥80 years
(Group I) and 152 (67.3%) were younger (Group II). Table 1 summarizes baseline
characteristics. Octogenarians were more frequently smokers (76.8% vs. 63.5%; p = 0.016)
and had higher rates of coronary artery disease (50.0% vs. 35.0%; p = 0.032) and chronic
kidney disease (41.9% vs. 24.2%; p = 0.007), with correspondingly lower median eGFR (62
(50–78) vs. 72.5 (60–88) mL/min/1.73 m2; p < 0.001). ASA class IV was more prevalent
among octogenarians (21.6% vs. 6.0%; p < 0.001). Juxtarenal AAAs predominated overall
(189 (83.6%)), with no difference in distribution between groups. Maximum aneurysm
diameter was larger in Group I (59.5 (53–70) mm vs. 55 (52–61) mm; p = 0.023), with no
variation in morphology.
<figure><img src="image_2.png" /><figcaption>**Figure 1.** Inclusion and exclusion criteria for patients undergoing elective open surgical repair. (OSR) of intact juxtarenal and pararenal abdominal aortic aneurysms (AAAs).</figcaption></figure>

<table><caption>**Table 1.** Baseline comparison of octogenarian patients vs. non-octogenarians.</caption><thead><tr><th>Variable</th><th>Total (n = 226) <sup>a,b</sup></th><th>≥80 y (n = 74) <sup>a,b</sup></th><th>&lt;80 y (n = 152) <sup>a,b</sup></th><th><i>p</i></th></tr></thead><tbody><tr><td>Age</td><td>71 (66–80)</td><td>80 (80–82)</td><td>67 (63–71)</td><td>&lt;0.001</td></tr><tr><td>Extent of aneurysm</td><td></td><td></td><td></td><td></td></tr><tr><td>Juxtarenal</td><td>189 (89.63)</td><td>66 (89.19)</td><td>123 (80.92)</td><td rowspan="2">0.115</td></tr><tr><td>Pararenal</td><td>37 (16.37)</td><td>8 (10.81)</td><td>29 (19.08)</td></tr><tr><td>Group</td><td></td><td></td><td></td><td></td></tr><tr><td>Montpellier</td><td>169 (74.78)</td><td>47 (63.51)</td><td>122 (80.26)</td><td rowspan="2">0.007</td></tr><tr><td>Lugano</td><td>57 (25.22)</td><td>27 (36.49)</td><td>30 (19.74)</td></tr><tr><td>Male</td><td>201 (89.33)</td><td>66 (89.19)</td><td>135 (89.4)</td><td>0.961</td></tr><tr><td>BMI</td><td>25.7 (22.7–28.3)</td><td>25.5 (22.9–28)</td><td>25.8 (22.5–28.3)</td><td>0.786</td></tr><tr><td>Diabetes mellitus</td><td>40 (17.78)</td><td>15 (20.27)</td><td>25 (16.56)</td><td>0.494</td></tr><tr><td>Hypertension</td><td>155 (68.98)</td><td>57 (77.03)</td><td>98 (64.9)</td><td>0.065</td></tr><tr><td>History of CHF</td><td>22 (9.78)</td><td>12 (16.22)</td><td>10 (6.62)</td><td>0.023</td></tr><tr><td>Smoke</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>163 (72.44)</td><td>116 (76.82)</td><td>47 (63.5)</td><td rowspan="3">0.016</td></tr><tr><td>No</td><td>51 (17.22)</td><td>26 (17.22)</td><td>25 (33.78)</td></tr><tr><td>Former</td><td>11 (4.89)</td><td>9 (5.96)</td><td>2 (2.70)</td></tr></tbody></table>
<table><caption>Table 1. *Cont.*</caption><thead><tr><th>Variable</th><th>Total (n = 226) <sup>a,b</sup></th><th>≥80 y (n = 74) <sup>a,b</sup></th><th>&lt;80 y (n = 152) <sup>a,b</sup></th><th>p</th></tr></thead><tbody><tr><td>Hystory of COPD</td><td>61 (27.11)</td><td>20 (27.03)</td><td>41 (27.15)</td><td>0.984</td></tr><tr><td>CAD</td><td>90 (40.00)</td><td>37 (50.00)</td><td>53 (35.10)</td><td>0.032</td></tr><tr><td>ASA</td><td></td><td></td><td></td><td></td></tr><tr><td>1</td><td>7 (3.12)</td><td>2 (2.70)</td><td>5 (3.33)</td><td rowspan="4">0.004</td></tr><tr><td>2</td><td>56 (25.00)</td><td>13 (17.57)</td><td>43 (28.67)</td></tr><tr><td>3</td><td>136 (60.71)</td><td>43 (58.11)</td><td>93 (62.00)</td></tr><tr><td>4</td><td>25 (11.16)</td><td>16 (21.62)</td><td>9 (6.00)</td></tr><tr><td>eGFR &lt; 60</td><td>67 (30.04)</td><td>31 (41.89)</td><td>36 (24.16)</td><td>0.007</td></tr><tr><td>KDIGO</td><td></td><td></td><td></td><td></td></tr><tr><td>1</td><td>32 (14.35)</td><td>2 (2.70)</td><td>30 (20.13)</td><td rowspan="5">0.001</td></tr><tr><td>2</td><td>124 (55.61)</td><td>41 (55.41)</td><td>83 (55.70)</td></tr><tr><td>3A</td><td>38 (17.04)</td><td>19 (25.68)</td><td>19 (12.75)</td></tr><tr><td>3B</td><td>17 (7.62)</td><td>9 (12.16)</td><td>8 (5.37)</td></tr><tr><td>4</td><td>4 (1.79)</td><td>2 (2.70)</td><td>2 (1.34)</td></tr><tr><td>5</td><td>8 (3.59)</td><td>1 (1.35)</td><td>7 (4.70)</td><td></td></tr><tr><td>Crea (mmol/L) pre-operative</td><td>92 (78–109)</td><td>96 (80–115)</td><td>91 (76–108)</td><td>0.227</td></tr><tr><td>eGFR (mL/min/1.73 m<sup>2</sup>)</td><td>70 (57.5–84)</td><td>62 (50–78)</td><td>72.5 (60–88)</td><td>&lt;0.001</td></tr><tr><td>AAA diameter (mm)</td><td>56 (52–64)</td><td>59.5 (53–70)</td><td>55 (52–61)</td><td>0.0226</td></tr><tr><td>Fusiform aneurysm</td><td>197 (87.56)</td><td>63 (85.14)</td><td>134 (88.74)</td><td>0.441</td></tr><tr><td>Previous abdominal surgery</td><td>38 (16.89)</td><td>10 (13.51)</td><td>28 (18.54)</td><td>0.344</td></tr></tbody></table>

AAA, Abdominal aortic aneurysm; BMI, body mass index (kg/m²); CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; crea, creatinine (mmol/L); eGFR, estimated glomerular filtration rate (mL/min/1.73 m²); y, years. <sup>a</sup> Data are presented as count (%) or median (Interquartile range). Percentage on column, when not otherwise specified. <sup>b</sup> Percentages are computed on the reported value excluding the missing ones.

## 3.2. Intraoperative Findings

The choice of laparotomic vs. retroperitoneal access did not differ between groups. Most repairs (71.6%) required suprarenal clamping; only □ve patients underwent supraceliac clamping, with no intergroup difference (p = 0.241). Octogenarians had longer total (30 (23–35) vs. 25 (20–36) min; p = 0.041) and partial renal ischemic times (29 (23–35) vs. 25 (20–32) min; p = 0.014), as well as greater blood loss (1900 (1300–3000) vs. 1200 (750–2000) mL; p = 0.007). Transfused volumes of whole blood (p = 0.071) and plasma (p = 0.429) were comparable. Additional intraoperative details are shown in Table 2.

<table><caption>Table 2. Comparison of intraoperative variables between octogenarian vs. non-octogenarian patients.</caption><thead><tr><th>Variable</th><th>Total (n = 226) <sup>a,e</sup></th><th>≥80 y (n = 74) <sup>a,e</sup></th><th>&lt;80 y (n = 152) <sup>a,e</sup></th><th>p</th></tr></thead><tbody><tr><td>Surgical approach</td><td></td><td></td><td></td><td>0.523</td></tr><tr><td>Laparotomy</td><td>127 (56.44)</td><td>44 (59.46)</td><td>83 (54.97)</td><td rowspan="2">0.241</td></tr><tr><td>Lombotomy</td><td>99 (44.00)</td><td>30 (40.54)</td><td>69 (45.70)</td></tr><tr><td>Type of graft</td><td></td><td></td><td></td><td>0.869</td></tr><tr><td>Straight tube</td><td>129 (57.33)</td><td>86 (56.95)</td><td>43 (58.11)</td><td rowspan="2">0.350</td></tr><tr><td>Bifurcated graft</td><td>95 (42.22)</td><td>65 (43.05)</td><td>30 (40.54)</td></tr><tr><td>Clamp site</td><td></td><td></td><td></td><td></td></tr><tr><td>Above CT</td><td>5 (2.22)</td><td>3 (1.99)</td><td>2 (2.70)</td><td rowspan="5">0.800</td></tr><tr><td>Above SMA</td><td>8 (3.56)</td><td>8 (5.30)</td><td>0 (0.0)</td></tr><tr><td>Above RAs</td><td>161 (71.56)</td><td>54 (72.97)</td><td>107 (70.86)</td></tr><tr><td>Above one RA</td><td>51 (22.67)</td><td>18 (24.32)</td><td>33 (21.85)</td></tr><tr><td>Adjunctive procedures</td><td>150 (66.37)</td><td>46 (62.16)</td><td>104 (68.42)</td></tr><tr><td>IMA reimplantation</td><td>92 (40.71)</td><td>31 (41.89)</td><td>61 (40.13)</td><td>0.0413</td></tr><tr><td>Total renal ischemic time <sup>b</sup>, min</td><td>27 (20–36)</td><td>30 (23–35)</td><td>25 (20–36)</td><td>0.0141</td></tr><tr><td>Partial renal ischemic time <sup>c</sup>, min</td><td>25 (20–32)</td><td>29 (23–35)</td><td>25 (20–32)</td><td>0.0141</td></tr><tr><td>Operative time, min</td><td>157 (121–232)</td><td>175 (129–255)</td><td>153.5 (117–226)</td><td>0.0762</td></tr><tr><td>Blood loss, mL</td><td>1500 (1000–2200)</td><td>1900 (1300–3000)</td><td>1200 (750–2000)</td><td>0.0074</td></tr><tr><td>Cell saver, mL</td><td>680 (473–1000)</td><td>750 (485–1100)</td><td>654.5 (453–1000)</td><td>0.6880</td></tr><tr><td>Transfusion <sup>d</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Whole blood, mL</td><td>135.43 ± 345.10</td><td>211.94 ± 454.45</td><td>97.44 ± 269.14</td><td>0.071</td></tr><tr><td>Plasma, mL</td><td>31.06 ± 137.59</td><td>40.00 ± 142.30</td><td>26.95 ± 135.68</td><td>0.429</td></tr><tr><td>Platelet, pool</td><td>3 (1.46)</td><td>0 (0)</td><td>3 (2.13)</td><td>0.236</td></tr><tr><td>Intraoperative balance, mL</td><td>3410 (2745–4870)</td><td>3300 (2270–4790)</td><td>3677.5 (2939.5–4922.5)</td><td>0.4314</td></tr></tbody></table>

IMA, inferior mesenteric artery; CT, celiac trunk; RA, renal artery; SMA, superior mesenteric artery; y, years. <sup>a</sup> Data are presented as count (%) or median (Interquartile range) if not otherwise specified. Percentage on column, when not otherwise specified. <sup>b</sup> Time during which at least one renal artery remained not perfused. <sup>c</sup> Time during which both renal arteries remained not perfused. <sup>d</sup> Even if skewed data were presented as mean ± Standard deviation for non-sense median values. <sup>e</sup> Percentages are computed on the reported value excluding the missing ones.
### 3.3. Postoperative Outcomes

Median length of stay was 7 (6–10) days in both groups (p = 0.521). MACE occurred more often in octogenarians (8.2% vs. 1.9%; p = 0.026), consisting of three cases each of new onset arrhythmia and CHF (all in Group I), one acute MI per group, and two hemorrhagic strokes (Group II). AKI incidence was similar, but severity was greater in octogenarians (stage 3: 3/13 vs. 0/19; p = 0.028). At 30 days, 16.5% of patients developed new renal impairment (eGFR < 60 mL/min/1.73 m2). Rates of other MAEs were comparable (Table 3), but minor complications were more frequent in Group I (11.4% vs. 4.3%; p = 0.005), predominantly delayed canalization, dyselectrolytemia, and urinary infection.

Thirty-day mortality was higher in octogenarians (9.5% vs. 0.7%; p < 0.001). Half of perioperative deaths (4/8) occurred intraoperatively or within 24 h in ICU; others were due to severe pancreatitis (day 10), colic ischemia (day 8), and pneumonia-related respiratory failure after prolonged intubation. The sole death in Group II occurred on day 5 from acute abdominal bleeding.

On univariate analysis, octogenarians had higher odds of MACE (OR 4.41, 95% CI 1.07–18.20; p = 0.040) and perioperative mortality (OR 15.67, 95% CI 1.89–129.91; p = 0.011).

After adjustment, associations remained significant (MACE: aOR 5.71, 95% CI 1.29–25.21; p = 0.022; mortality: aOR 18.55, 95% CI 2.01–170.53; p = 0.013). Subgroup analysis in octogenarians identified non-fusiform aneurysm shape as a predictor of MACE (OR 8.62, 95% CI 1.44–51.02; p = 0.018) and intraoperative blood loss as a predictor of mortality (OR 1.01, 95% CI 1.00–1.10; p = 0.050); no predictors emerged in younger patients.

<table><caption>Table 3. Perioperative outcomes.</caption><thead><tr><th>Variable</th><th>Total (n = 226) <sup>a,b</sup></th><th>≥ 80 y (n = 74) <sup>a,b</sup></th><th>&lt; 80 y (n = 152) <sup>a,b</sup></th><th>p</th></tr></thead><tbody><tr><td>MACE</td><td>9 (4.02)</td><td>6 (8.22)</td><td>3 (1.99)</td><td>0.026</td></tr><tr><td>MI</td><td>2 (0.88)</td><td>1 (1.35)</td><td>1 (0.66)</td><td>0.601</td></tr><tr><td>CHF</td><td>3 (1.33)</td><td>3 (4.05)</td><td>0 (0)</td><td>0.012</td></tr><tr><td>Arrhythmia</td><td>3 (1.33)</td><td>3 (4.05)</td><td>0 (0)</td><td>0.012</td></tr><tr><td>Stroke</td><td>2 (0.89)</td><td>0</td><td>2 (1.32)</td><td>0.323</td></tr><tr><td>Pulmonary complications</td><td>25 (11.16)</td><td>6 (8.22)</td><td>19 (12.58)</td><td>0.331</td></tr><tr><td>Bowel ischemia</td><td>12 (5.36)</td><td>4 (5.48)</td><td>8 (5.30)</td><td>0.955</td></tr><tr><td>Graft infection</td><td>4 (1.77)</td><td>0 (0)</td><td>4 (2.63)</td><td>0.159</td></tr><tr><td>ALI</td><td>14 (6.19)</td><td>4 (5.41)</td><td>10 (6.58)</td><td>0.731</td></tr><tr><td>SCI</td><td>2 (0.88)</td><td>1 (1.35)</td><td>1 (0.66)</td><td>0.601</td></tr><tr><td>Visceral impairment</td><td>4 (1.77)</td><td>1 (1.35)</td><td>3 (1.97)</td><td>0.739</td></tr><tr><td>Delirium</td><td>5 (2.21)</td><td>3 (4.05)</td><td>2 (1.32)</td><td>0.189</td></tr><tr><td>Haemorrhagic complications</td><td>9 (3.98)</td><td>5 (6.76)</td><td>4 (2.63)</td><td>0.137</td></tr><tr><td>Composite MAE</td><td>60 (26.55)</td><td>22 (29.73)</td><td>38 (25.00)</td><td>0.450</td></tr><tr><td>Minor complication</td><td>14 (6.70)</td><td>8 (11.43)</td><td>6 (4.32)</td><td>0.005</td></tr><tr><td>Any kind of complications</td><td>80 (35.40)</td><td>30 (40.54)</td><td>50 (32.89)</td><td>0.259</td></tr><tr><td>Re-Intervention</td><td>33 (14.73)</td><td>9 (12.33)</td><td>24 (15.89)</td><td>0.480</td></tr><tr><td>AKI total</td><td>32 (43.84)</td><td>13 (43.33)</td><td>19 (44.19)</td><td>0.942</td></tr><tr><td>AKI</td><td></td><td></td><td></td><td></td></tr><tr><td>KDIGO 1</td><td>23 (31.51)</td><td>7 (23.33)</td><td>16 (37.21)</td><td rowspan="3">0.134</td></tr><tr><td>KDIGO 2</td><td>6 (8.22)</td><td>3 (10.00)</td><td>3 (6.98)</td></tr><tr><td>KDIGO 3</td><td>3 (4.11)</td><td>3 (10.00)</td><td>0 (0.00)</td></tr><tr><td>30-day kidney impairment (new onset)</td><td>23 (16.55)</td><td>6 (15.38)</td><td>17 (17.00)</td><td>0.818</td></tr><tr><td>Hospital stay, days</td><td>7 (6–10)</td><td>8 (6–11)</td><td>7 (6–10)</td><td>0.521</td></tr><tr><td>30-day mortality</td><td>8 (3.56)</td><td>7 (9.46)</td><td>1 (0.66)</td><td>0.001</td></tr></tbody></table>

ALL, acute limb ischemia; AKI, acute kidney ischemia; CHE, chronic heart failure; MACE, major adverse cardiovascular events; MAE, major adverse events; MI, myocardial infarction; SCI, spinal cord ischemia; y, years * Data are presented as count (%) or median (Interquartile range). Percentage on column, when not otherwise specified.

b Percentages are computed on the reported value excluding the missing ones.
### 3.4. Follow-Up

Median follow-up was 42.7 (23–63) months and the average follow-up index 0.78 with no differences between groups (octogenarians vs. non-octogenarians) and centers. Freedom from AAA-related death at 1 and 5 years was 91.7% and 89.2% in Group I vs. 98.6% and 97.8% in Group II (Figure 2). Overall survival was not significantly different, though a trend toward higher non-AAA-related mortality was noted in octogenarians (Figure 3). The cumulative 5-year incidence of procedure-related reintervention was 0% in Group I and 2.6% in Group II (p = 0.209). In the Cox model, octogenarian status was not a predictor of overall (p = 0.213) or procedure/aneurysm-related mortality (p = 0.909).

<figure><img src="image_3.png" /><figcaption>Figure 2. Freedom from AAA/procedure related death among the study groups LogRank = 0.901.</figcaption></figure>

<table><thead><tr><th rowspan="2">Months</th><th colspan="3">Age ≥ 80</th><th colspan="3">Age < 80</th></tr><tr><th>%</th><th>SE%</th><th>95% CI</th><th>%</th><th>SE%</th><th>95% CI</th></tr></thead><tbody><tr><td>12</td><td>91.72</td><td>3.24</td><td>82.5–96.2</td><td>98.6</td><td>0.9</td><td>94.6–99.7</td></tr><tr><td>24</td><td>91.72</td><td>3.24</td><td>82.5–96.2</td><td>97.8</td><td>1.2</td><td>93.4–99.3</td></tr><tr><td>36</td><td>91.72</td><td>3.24</td><td>82.5–96.2</td><td>97.8</td><td>1.2</td><td>93.4–99.3</td></tr><tr><td>48</td><td>89.17</td><td>4.03</td><td>78.0–94.8</td><td>97.8</td><td>1.2</td><td>93.4–99.3</td></tr><tr><td>60</td><td>89.17</td><td>4.03</td><td>78.0–94.8</td><td>97.8</td><td>1.2</td><td>93.4–99.3</td></tr></tbody></table>

CI, Confidence Interval; SE, Standard Error; y, years.
<figure><img src="image_4.png" /><figcaption>Figure 3. Overall survival among the study groups LogRank = 0.209.</figcaption></figure>

<table><thead><tr><th rowspan="2">Months</th><th colspan="3">Age ≥ 80</th><th colspan="3">Age < 80</th></tr><tr><th>%</th><th>SE%</th><th>95% CI</th><th>%</th><th>SE%</th><th>95% CI</th></tr></thead><tbody><tr><td>12</td><td>89.04</td><td>3.66</td><td>79.3-94.4</td><td>93.30</td><td>2.05</td><td>87.9-96.3</td></tr><tr><td>24</td><td>89.04</td><td>3.66</td><td>79.3-94.4</td><td>91.16</td><td>2.34</td><td>85.3-94.8</td></tr><tr><td>36</td><td>86.76</td><td>4.22</td><td>75.8-93.0</td><td>89.46</td><td>2.59</td><td>83.1-93.5</td></tr><tr><td>48</td><td>81.79</td><td>5.24</td><td>68.7-89.8</td><td>88.39</td><td>2.78</td><td>81.6-92.3</td></tr><tr><td>60</td><td>79.15</td><td>5.70</td><td>65.2-88.0</td><td>86.62</td><td>3.23</td><td>78.7-91.7</td></tr></tbody></table>

CI, Confidence Interval; SE, Standard Error; y, years.

## 3.5. Propensity-Matched Analysis

PSM achieved an Area Under the Curve of 0.73 (95% CI 0.66–0.80). The matched cohort (Table 4) included 73 octogenarians and 44 younger patients with balanced baseline and intraoperative characteristics except for median eGFR (62 (50–78) vs. 74.5 (58.5–85); p = 0.014). In the matched analysis, MACE remained more frequent in octogenarians (p = 0.047), and 30-day mortality remained higher (p = 0.033). No differences were observed in LOS, mid-term survival, or reintervention rates (Table 5).
<table><caption>**Table 4.** Baseline and Intraoperative variable comparison between octogenarians and non-octogenarians after the 1:1 propensity score matching.</caption><thead><tr><th>Variable</th><th>Total (n = 117) <sup>a,b</sup></th><th>≥80 y (n = 73) <sup>a,b</sup></th><th>&lt;80 y (n = 44) <sup>a,b</sup></th><th>p</th></tr></thead><tbody><tr><td>Age</td><td>80 (70-81)</td><td>80 (80-82)</td><td>66.5 (65-70)</td><td>&lt;0.001</td></tr><tr><td>Extent of aneurysm</td><td></td><td></td><td></td><td></td></tr><tr><td>Iuxtarenal</td><td>101 (86.32)</td><td>65 (89.04)</td><td>36 (81.82)</td><td rowspan="2">0.271</td></tr><tr><td>Pararenal</td><td>16 (13.68)</td><td>8 (10.96)</td><td>8 (18.18)</td></tr><tr><td>Group</td><td></td><td></td><td></td><td></td></tr><tr><td>Montpellier</td><td>79 (52.24)</td><td>46 (63.01)</td><td>33 (71.74)</td><td rowspan="2">0.108</td></tr><tr><td>Lugano</td><td>37 (31.62)</td><td>27 (36.99)</td><td>10 (22.73)</td></tr><tr><td>Male</td><td>104 (89.89)</td><td>65 (89.04)</td><td>39 (88.64)</td><td>0.946</td></tr><tr><td>BMI</td><td>25.68 ± 4.08</td><td>25.64 ± 3.83</td><td>25.76 ± 4.51</td><td>0.880</td></tr><tr><td>Diabetes mellitus</td><td>26 (22.2)</td><td>14 (19.18)</td><td>12 (27.27)</td><td>0.308</td></tr><tr><td>Hypertension</td><td>90 (76.92)</td><td>56 (76.71)</td><td>34 (77.27)</td><td>0.944</td></tr><tr><td>History of CHF</td><td>15 (12.82)</td><td>11 (15.07)</td><td>4 (9.09)</td><td>0.349</td></tr><tr><td>Smoke</td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>78 (66.67)</td><td>47 (64.38)</td><td>31 (70.45)</td><td rowspan="3">0.612</td></tr><tr><td>No</td><td>36 (30.25)</td><td>24 (32.88)</td><td>12 (26.09)</td></tr><tr><td>Former</td><td>4 (3.42)</td><td>2 (2.74)</td><td>2 (4.55)</td></tr><tr><td>Hystory of COPD</td><td>30 (25.64)</td><td>20 (27.40)</td><td>10 (22.73)</td><td>0.575</td></tr><tr><td>CAD</td><td>58 (49.57)</td><td>37 (50.68)</td><td>21 (47.73)</td><td>0.757</td></tr><tr><td>ASA</td><td></td><td></td><td></td><td></td></tr><tr><td>1</td><td>2 (1.71)</td><td>2 (2.74)</td><td>0 (0.00)</td><td rowspan="4">0.105</td></tr><tr><td>2</td><td>23 (19.66)</td><td>13 (17.81)</td><td>10 (22.73)</td></tr><tr><td>3</td><td>73 (62.39)</td><td>42 (57.53)</td><td>31 (70.45)</td></tr><tr><td>4</td><td>19 (16.24)</td><td>16 (21.92)</td><td>3 (6.82)</td></tr><tr><td>eGFR &lt; 60</td><td>42 (35.90)</td><td>30 (41.10)</td><td>12 (27.27)</td><td>0.131</td></tr><tr><td>KDIGO</td><td></td><td></td><td></td><td></td></tr><tr><td>1</td><td>8 (6.84)</td><td>2 (2.74)</td><td>6 (15.22)</td><td rowspan="5">0.060</td></tr><tr><td>2</td><td>67 (57.26)</td><td>41 (56.16)</td><td>26 (59.09)</td></tr><tr><td>3A</td><td>25 (21.37)</td><td>18 (24.66)</td><td>7 (15.91)</td></tr><tr><td>3B</td><td>11 (9.40)</td><td>9 (12.33)</td><td>2 (4.55)</td></tr><tr><td>4</td><td>2 (1.71)</td><td>2 (2.74)</td><td>0 (0.0)</td></tr><tr><td>5</td><td>4 (3.42)</td><td>1 (1.37)</td><td>3 (6.82)</td><td></td></tr><tr><td>Creatinine (mmol/L) pre-operative</td><td>92 (80-111)</td><td>96 (80-111)</td><td>87 (78.5-112)</td><td>0.405</td></tr><tr><td>eGFR (mL/min/1.73 m<sup>2</sup>)</td><td>66 (56-82)</td><td>62 (50-78)</td><td>74.5 (58.5-85)</td><td>0.014</td></tr><tr><td>AAA diameter (mm)</td><td>58 (52-67)</td><td>59 (53-70)</td><td>54.5 (50-61)</td><td>0.197</td></tr><tr><td>Fusiform aneurysm</td><td>96 (82.05)</td><td>62 (84.93)</td><td>34 (77.27)</td><td>0.296</td></tr><tr><td>Previous abdominal surgery</td><td>17 (14.53)</td><td>10 (13.70)</td><td>7 (15.91)</td><td>0.742</td></tr><tr><td>Surgical approach</td><td></td><td></td><td></td><td>0.984</td></tr><tr><td>Laparotomy</td><td>69 (58.97)</td><td>43 (58.90)</td><td>26 (63.04)</td><td rowspan="2">0.793</td></tr><tr><td>Lombotomy</td><td>48 (41.03)</td><td>30 (41.10)</td><td>18 (39.96)</td></tr><tr><td>Type of graft</td><td></td><td></td><td></td><td></td></tr><tr><td>Straight tube</td><td>69 (58.97)</td><td>42 (57.53)</td><td>27 (61.36)</td><td rowspan="2">0.275</td></tr><tr><td>Bifurcated graft</td><td>47 (40.17)</td><td>30 (41.10)</td><td>17 (38.64)</td></tr><tr><td>Clamp site</td><td></td><td></td><td></td><td></td></tr><tr><td>Above CT</td><td>3 (2.56)</td><td>2 (2.74)</td><td>1 (2.27)</td><td rowspan="4">0.275</td></tr><tr><td>Above SMA</td><td>2 (1.71)</td><td>0 (0)</td><td>2 (4.55)</td></tr><tr><td>Above RAs</td><td>86 (73.50)</td><td>53 (72.60)</td><td>33 (75.00)</td></tr><tr><td>Above one RA</td><td>26 (22.22)</td><td>18 (24.66)</td><td>8 (18.18)</td></tr><tr><td>Adjunctive procedures</td><td>79 (67.52)</td><td>45 (61.64)</td><td>34 (77.27)</td><td>0.080</td></tr><tr><td>IMA reimplantation</td><td>51 (43.59)</td><td>30 (41.10)</td><td>21 (47.73)</td><td>0.483</td></tr><tr><td>Total renal ischemic time <sup>c</sup>, min</td><td>28 (23-38)</td><td>29.5 (23-36)</td><td>28 (20-41)</td><td>0.685</td></tr><tr><td>Partial renal ischemic time <sup>d</sup>, min</td><td>28 (22-35)</td><td>28.5 (23-35)</td><td>28 (20-37)</td><td>0.538</td></tr><tr><td>Operative time, min</td><td>175 (133-236)</td><td>175 (132-255)</td><td>171.5 (133.5-222.5)</td><td>0.589</td></tr><tr><td>Blood loss, mL</td><td>1800 (1000-2600)</td><td>1900 (1300-3000)</td><td>1150 (600-2000)</td><td>0.124</td></tr><tr><td>Cell saver, mL</td><td>744 (485-1110)</td><td>758 (485-1100)</td><td>700 (457-1162)</td><td>0.824</td></tr></tbody></table>
<table><caption>**Table 4.** *Cont.*</caption><thead><tr><th>Variable</th><th>Total (n = 117) <sup>a,b</sup></th><th>≥80 y (n = 73) <sup>a,b</sup></th><th>&lt;80 y (n = 44) <sup>a,b</sup></th><th>p</th></tr></thead><tbody><tr><td>Transfusion <sup>e</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Whole blood, mL</td><td>193.48 ± 431.81</td><td>214.92 ± 456.97</td><td>156.34 ± 386.98</td><td>0.491</td></tr><tr><td>Plasma, mL</td><td>33.3 ± 126.12</td><td>40.62 ± 143.34</td><td>21.05 ± 90.51</td><td>0.451</td></tr><tr><td>Platelet, pool</td><td>0 (0.0)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Intraoperative balance, mL</td><td>3387.5 (2370–5150)</td><td>3300 (2270–4790)</td><td>3820 (2700–5370)</td><td>0.457</td></tr></tbody></table>

AAA, Abdominal aortic aneurysm; BMI, body mass index (kg/m²); CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CT, celiac trunk; eGFR, estimated glomerular filtration rate (mL/min/1.73 m²); IMA, inferior mesenteric artery; RA, renal artery; SMA, superior mesenteric artery; y, years. <sup>a</sup> Data are presented as count (%) or median (Interquartile range). Percentage on column, when not otherwise specified. <sup>b</sup> Percentages are computed on the reported value excluding the missing one. <sup>c</sup> Time during which at least one renal artery remained not perfused. <sup>d</sup> Time during which both renal arteries remained not perfused. <sup>e</sup> Even if skewed data were presented as mean ± Standard deviation for non-sense median values.

<table><caption>**Table 5.** Perioperative results after the 1:1 propensity score matching.</caption><thead><tr><th>Variable</th><th>Total (n = 117) <sup>a,b</sup></th><th>≥80 y (n = 73) <sup>a,b</sup></th><th>&lt;80 y (n = 44) <sup>a,b</sup></th><th>p</th></tr></thead><tbody><tr><td>MACE</td><td>9 (7.69)</td><td>7 (9.59)</td><td>3 (6.81)</td><td>0.047</td></tr><tr><td>MI</td><td>2 (1.71)</td><td>1 (1.37)</td><td>1 (2.27)</td><td>0.613</td></tr><tr><td>CHF</td><td>3 (2.56)</td><td>3 (4.05)</td><td>0 (0)</td><td>0.239</td></tr><tr><td>Arrhythmia</td><td>3 (2.56)</td><td>3 (4.11)</td><td>0 (0)</td><td>0.239</td></tr><tr><td>Stroke</td><td>1 (0.86)</td><td>0 (0)</td><td>1 (2.27)</td><td>0.379</td></tr><tr><td>Pulmonary complications</td><td>13 (11.21)</td><td>6 (8.33)</td><td>7 (15.91)</td><td>0.170</td></tr><tr><td>Bowel ischemia</td><td>6 (5.17)</td><td>4 (5.56)</td><td>2 (4.55)</td><td>0.588</td></tr><tr><td>Graft infection</td><td>1 (0.85)</td><td>0 (0)</td><td>1 (2.27)</td><td>0.376</td></tr><tr><td>ALI</td><td>9 (7.69)</td><td>4 (5.48)</td><td>5 (11.36)</td><td>0.210</td></tr><tr><td>SCI</td><td>1 (0.85)</td><td>1 (1.37)</td><td>0 (0)</td><td>0.624</td></tr><tr><td>Visceral impairment</td><td>2 (1.71)</td><td>1 (1.37)</td><td>1 (2.27)</td><td>0.613</td></tr><tr><td>Delirium</td><td>4 (3.42)</td><td>3 (4.11)</td><td>1 (2.27)</td><td>0.516</td></tr><tr><td>Haemorrhagic complications</td><td>7 (5.98)</td><td>5 (6.85)</td><td>2 (4.55)</td><td>0.470</td></tr><tr><td>Composite MAE</td><td>34 (29.06)</td><td>22 (30.14)</td><td>12 (27.27)</td><td>0.741</td></tr><tr><td>Minor complications</td><td>9 (8.04)</td><td>8 (11.59)</td><td>1 (2.33)</td><td>0.079</td></tr><tr><td>Any kind of complications</td><td>48 (35.40)</td><td>30 (41.10)</td><td>18 (39.13)</td><td>0.831</td></tr><tr><td>Re-Intervention</td><td>17 (14.66)</td><td>9 (12.50)</td><td>8 (18.18)</td><td>0.401</td></tr><tr><td>AKI total</td><td>16 (13.68)</td><td>13 (17.81)</td><td>3 (6.82)</td><td>0.094</td></tr><tr><td>AKI</td><td></td><td></td><td></td><td></td></tr><tr><td>KDIGO 1</td><td>10 (28.57)</td><td>7 (23.33)</td><td>3 (27.27)</td><td rowspan="3">0.459</td></tr><tr><td>KDIGO 2</td><td>3 (6.12)</td><td>3 (10.00)</td><td>0 (0.00)</td></tr><tr><td>KDIGO 3</td><td>3 (6.12)</td><td>3 (10.00)</td><td>0 (0.00)</td></tr><tr><td>30-day renal impairment (new onset)</td><td>9 (13.64)</td><td>6 (15.38)</td><td>3 (11.11)</td><td>0.454</td></tr><tr><td>Hospital stay, days</td><td>8 (6–11)</td><td>8 (6–11)</td><td>8 (6–11)</td><td>0.929</td></tr><tr><td>30-day mortality</td><td>7 (5.98)</td><td>7 (9.59)</td><td>0 (0.00)</td><td>0.033</td></tr></tbody></table>

ALI, acute limb ischemia; AKI, acute kidney ischemia; CHF, chronic heart failure; MACE, major adverse cardiovascular events; MAE, major adverse events; MI, myocardial infarction; SCI, spinal cord ischemia, y, years. <sup>a</sup> Data are presented as count (%) or median (Interquartile range). Percentage on column, when not otherwise specified.

## 4. Discussion

This study demonstrates that open surgical repair (OSR) of complex abdominal aortic aneurysms (cAAAs) is associated with low short-term mortality in the general population, but octogenarians face significantly higher early mortality and major adverse cardiovascular events (MACE). Despite this increased early risk, mid-term survival and freedom from

<footnote><sup>b</sup> Percentages are computed on the reported value excluding the missing ones.</footnote>
reintervention were similar between age groups, suggesting that OSR remains a viable treatment option for carefully selected elderly patients—even in the era of fenestrated and branched endovascular aortic repair (F/BEVAR).

With the global population aging, vascular surgeons are increasingly confronted with cAAA in elderly patients. While F/BEVAR has expanded minimally invasive repair options, anatomic complexity or device limitations may still necessitate OSR. Contemporary literature often favors endovascular techniques for octogenarians, assuming that early mortality reduction justifies potential increases in late adverse events and reintervention [8–12,14–17,19–21,30,32]. This study directly addresses the issue by evaluating OSR outcomes in octogenarians compared with younger patients.

Results show a significantly higher 30-day mortality in octogenarians (9.5% vs. 0.7%), a difference that persisted after adjustment for confounders, indicating an intrinsic age related vulnerability. Most early deaths in elderly patients occurred intraoperatively or within the first 24 h, highlighting the hemodynamic stress of OSR. The increased incidence of MACE in octogenarians was driven primarily by postoperative heart failure and arrhythmias rather than ischemic events, consistent with findings from Zil-E-Ali et al. [27]. in elderly FEVAR patients. This underscores the importance of aggressive preoperative cardiac optimization, meticulous intraoperative hemodynamic control, and vigilant postoperative monitoring.

Interestingly, severe non-cardiovascular complications occurred at similar rates between age groups. Although octogenarians experienced longer renal ischemia times and greater blood loss, AKI incidence was comparable, likely reflecting standardized renal protection strategies—such as cold saline perfusion—and rigorous postoperative monitoring. However, when AKI occurred in elderly patients, it was more often severe, aligning with prior reports linking chronic kidney disease to poor perioperative outcomes.

Reported 30-day mortality rates for F/BEVAR in octogenarians range from 4% to 7.3% [17,22,27,32], slightly lower than in this OSR cohort. However, 5-year overall survival after F/BEVAR is reported at only 27–50%, markedly lower than in this series [14,17,32,37]. Similarly, pooled meta-analyses show 3- and 5-year freedom from reintervention after FEVAR at 80.9% and 73.8%, respectively [30], compared with >95% aneurysm-related survival and no reinterventions in our octogenarians at 5 years. Part of the observed favorable mid-term outcomes may be explained by the restriction of OSR to elderly patients maintaining relatively preserved physiological and functional status. Nevertheless, these results suggest that while OSR in octogenarians carries a moderately higher early mortality than F/BEVAR, this must be weighed against superior mid-term durability, which is particularly valuable for patients with a good quality of life and for those with logistical, financial and geographical barriers to follow-up.

In the study cohort, mid-term survival and freedom from reintervention did not differ significantly between octogenarians and younger patients. This mirrors findings by Mahmood et al. [3], who reported similar technical success and complication rates across age groups for F/BEVAR, but with lower long-term survival in elderly patients due to competing risks. Our results suggest that, in selected octogenarians with a life expectancy of ≥5 years, OSR can achieve durable aneurysm exclusion comparable to younger patients.
A subgroup analysis identified non-fusiform aneurysm morphology as an independent predictor of MACE across all ages. This phenotype likely reflects greater technical complexity, prolonged clamp time, and increased bleeding risk. In contrast, aneurysm diameter was not associated with adverse events. These findings support incorporating aneurysm morphology rather than size into surgical risk assessment.

Length of hospital stay was similar between age groups, suggesting that, when carefully selected, octogenarians can recover from OSR as efficiently as younger patients. This challenges the assumption that chronological age alone predicts prolonged postoperative recovery [27].

The data from this study underscore the importance of individualized risk assessment rather than rigid age cutoffs. Key considerations include functional status, frailty, nutritional reserve, and projected life expectancy. Optimal decision-making requires a multidisciplinary approach involving vascular surgeons, anesthesiologists, cardiologists, and geriatricians, with shared decision-making to align surgical risks with patient values and goals [42].

## Limitations

This study's retrospective design, small sample size (particularly in the octogenarian subgroup), and potential selection bias limit generalizability of the study. All cases were performed at high-volume centers with substantial OSR expertise, which may not reflect outcomes in lower-volume settings. Some intraoperative measures, such as blood loss, may be prone to reporting inaccuracies. Additionally, follow-up was limited to five years, precluding assessment of longer-term durability. Prospective, multicenter studies incorporating frailty metrics are needed to validate these findings.

Prospective, multicenter studies incorporating frailty metrics are needed to validate these findings. In addition, our study did not include data on biomarkers known to influence outcomes after open AAA repair, such as NT-proBNP, troponins, cystatin C, intercellular adhesion molecule-1, or inflammatory markers including IL-1. Emerging biomarkers, such as bioactive adrenomedullin and butyrylcholinesterase, may further help identify the most vulnerable patients within the octogenarian population. Unfortunately, these biomarker measurements were not available for the patients included in this study.

# 5. Conclusions

In appropriately selected octogenarians, OSR of cAAA offers excellent mid-term survival and durability, with reintervention rates lower than most contemporary endovascular series. Although early mortality is significantly higher than in younger patients, these results argue against automatic exclusion of elderly individuals from OSR solely based on age.
**Author Contributions:**

Conceptualization, F.A., G.P., P.F.R. and A.R.; Methodology, F.A., G.P., L.G. and D.S.; Validation, G.P., A.R., L.G., A.A., L.C. and P.A.; Formal Analysis, F.A., G.P., A.R., L.G., A.A., L.C. and P.A.; Data Curation, A.A., P.F.R., P.G., F.A., J.G. and L.E.; Writing—Original Draft Preparation, F.A. and A.A.; Writing—Review and Editing, G.P., A.R., L.G., L.C., A.A., D.S. and L.E.; Visualization, P.G., D.S., L.G., L.C. and P.A.; Supervision, G.P., A.R., L.C. and P.A. All authors have read and agreed to the published version of the manuscript.

**Funding:**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Institutional Review Board Statement:**

The study was approved by the local Ethics Committee (2024-00501 CE 4561, approval on 15 May 2024). Helsinki Declaration and its later amendments were respected and the data underlying this article will be shared on reasonable request to the corresponding author. All data used in this work are anonymized and accessible only to the authors of this article. According to French regulations, studies based exclusively on fully anonymized data do not require specific approval from the Commission Nationale de l'Informatique et des Libertés (CNIL). When anonymization is effective, the data are no longer considered personal data and the requirements of the GDPR (and CNIL approval) do not apply. https://www.cnil.fr/fr/technologies/lanonymisation-de-donnees-personnelles, https://www.cnil.fr/fr/identi-lesdonnees-personnelles (accessed on 27 September 2025).

**Informed Consent Statement:**

All surviving patients were sent a non-opposition consent form, except those recruited from one of the two centers where, since 2021, all participants have provided signed informed consent for clinical research and data analysis.

**Data Availability Statement:**

The data presented in this study are available on reasonable request from the corresponding author.

**Conflicts of Interest:**

The authors declare no conflicting interests for this topic.
Abbreviations

The following abbreviations are used in this manuscript: fEVAR Fenestrated Endovascular Aneurysm Repair; bEVAR Branched Endovascular Aneurysm Repair; f/bEVAR Fenestrated/Branched Endovascular Aneurysm Repair; cAAA Complex Abdominal Aortic Aneurysm; OSR Open Surgery Repair; jAAA Juxtarenal Abdominal Aortic Aneurysm; pAAA Pararenal Abdominal Aortic Aneurysm; AAA Abdominal Aortic Aneurysm; ASA American Society of Anesthesiologists (score); ESC European Society of Cardiology; AHA American Heart Association; ACC American College of Cardiology; HFSA Heart Failure Society of America; CKD Chronic Kidney Disease; eGFR Estimated Glomerular Filtration Rate; KDIGO Kidney Disease: Improving Global Outcomes; MACE Major Adverse Cardiovascular Events; HF Heart Failure; LOS Length of Stay; AKI Acute Kidney Injury; MAEs Major Adverse Events; IQR Interquartile Range; PSM Propensity Score Matching

References

1. Wanhainen, A.; Van Herzeele, I.; Bastos Goncalves, F.; Bellmunt Montoya, S.; Berard, X.; Boyle, J.R.; D'Oria, M.; Prendes, C.F.; Karkos, C.D.; Kazimierczak, A.; et al. Editor's Choice—European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. **2024**, 67, 192–331. [CrossRef] [PubMed]

2. Suckow, B.D.; Goodney, P.P.; Columbo, J.A.; Kang, R.; Stone, D.H.; Sedrakyan, A.; Cronenwett, J.L.; Fillinger, M.F. National Trends in Open Surgical, Endovascular, and Branched-Fenestrated Endovascular Aortic Aneurysm Repair in Medicare Patients. J. Vasc. Surg. **2018**, 67, 1690–1697.e1. [CrossRef] [PubMed]

3. Mohamed, N.; Galyfos, G.; Anastasiadou, C.; Sachmpatzidis, I.; Kikiras, K.; Papapetrou, A.; Giannakakis, S.; Kastrisios, G.; Papacharalampous, G.; Geroulakos, G.; et al. Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal Aortic Aneurysms: A Systematic Review. Ann. Vasc. Surg. **2020**, 63, 399–408. [CrossRef]

4. Chaikof, E.L.; Dalman, R.L.; Eskandari, M.K.; Jackson, B.M.; Lee, W.A.; Mansour, M.A.; Mastracci, T.M.; Mell, M.; Murad, M.H.; Nguyen, L.L.; et al. The Society for Vascular Surgery Practice Guidelines on the Care of Patients with an Abdominal Aortic Aneurysm. J. Vasc. Surg. **2018**, 67, 2–77.e2. [CrossRef]

5. Huang, Y.; Colglazier, J.; Pochettino, A.; Kalra, M.; Bower, T.C.; Greason, K.L.; Mendes, B.C.; Tenorio, E.R.; Gloviczki, P.; Harmsen, W.S.; et al. Treatment Trends and Outcomes of Endovascular versus Open Thoracoabdominal Aortic Aneurysm Repair—A Single-Center Comparative Cohort Study. Ann. Surg. **2025**. [CrossRef]

6. Oderich, G.S.; Tenorio, E.R.; Mendes, B.C.; Lima, G.B.B.; Marcondes, G.B.; Saqib, N.; Hofer, J.; Wong, J.; Macedo, T.A. Midterm Outcomes of a Prospective, Nonrandomized Study to Evaluate Endovascular Repair of Complex Aortic Aneurysms Using Fenestrated-Branched Endografts. Ann. Surg. **2021**, 274, 491–499. [CrossRef]
7. Antoniou, G.A.; Juszczak, M.T.; Antoniou, S.A.; Katsargyris, A.; Haulon, S. Editor's Choice—Fenestrated or Branched Endovascular versus Open Repair for Complex Aortic Aneurysms: Meta-Analysis of Time to Event Propensity Score Matched Data. Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. **2021**, *61*, 228–237. [CrossRef]

8. Yamaguchi, T.; Nakai, M.; Sumita, Y.; Nishimura, K.; Nagai, T.; Anzai, T.; Sakata, Y.; Ogino, H. Impact of Endovascular Repair on the Outcomes of Octogenarians with Ruptured Abdominal Aortic Aneurysms: A Nationwide Japanese Study. Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. **2020**, *59*, 219–225. [CrossRef]

9. Makaloski, V.; Kölbel, T.; Rohlffs, F.; Behrendt, C.A.; Law, Y.; Debus, E.S.; Tsilimparis, N. Early Outcomes After Branched and Fenestrated Endovascular Aortic Repair in Octogenarians. Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. **2018**, *56*, 818–825. [CrossRef]

10. Timaran, D.E.; Knowles, M.; Ali, T.; Timaran, C.H. Fenestrated Endovascular Aneurysm Repair among Octogenarians at High and Standard Risk for Open Repair. J. Vasc. Surg. **2017**, *66*, 354–359. [CrossRef]

11. Motta, F.; Oderich, G.S.; Tenorio, E.R.; Schanzer, A.; Timaran, C.H.; Schneider, D.; Sweet, M.P.; Beck, A.W.; Eagleton, M.J.; Farber, M.A.; et al. Fenestrated-Branched Endovascular Aortic Repair Is a Safe and Effective Option for Octogenarians in Treating Complex Aortic Aneurysm Compared with Nonoctogenarians. J. Vasc. Surg. **2021**, *74*, 353–362.e1. [CrossRef]

12. Pini, R.; Faggioli, G.; Gallitto, E.; Mascoli, C.; Fenelli, C.; Vacirca, A.; Gargiulo, M. Predictors of Survival in Patients Over 80 Years Old Treated with Fenestrated and Branched Endograft. Ann. Vasc. Surg. **2020**, *67*, 52–58. [CrossRef] [PubMed]

13. Aftab, M.; Songdechakraiwut, T.; Green, S.Y.; Zarda, S.; Price, M.D.; Nalty, C.C.; Preventza, O.; de la Cruz, K.I.; LeMaire, S.A.; Coselli, J.S. Contemporary Outcomes of Open Thoracoabdominal Aortic Aneurysm Repair in Octogenarians. J. Thorac. Cardiovasc. Surg. **2015**, *149*, S134–S141. [CrossRef] [PubMed]

14. Mahmood, D.N.; Forbes, S.M.; Rocha, R.; Tan, K.; Ouzounian, M.; Chung, J.C.-Y.; Lindsay, T.F. Outcomes in Octogenarians after Thoracoabdominal and Juxtarenal Aortic Aneurysm Repair Using Fenestrated-Branched Devices: A Treatment. J. Vasc. Surg. **2023**, *77*, 694–703.e3. [CrossRef] [PubMed]

15. Kontopodis, N.; Galanakis, N.; Charalambous, S.; Matsagkas, M.; Giannoukas, A.D.; Tsetis, D.; Ioannou, C.V.; Antoniou, G.A. Editor's Choice—Endovascular Aneurysm Repair in High Risk Patients: A Systematic Review and Meta-Analysis. Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. **2022**, *64*, 461–474. [CrossRef]

16. Henstra, L.; Yazar, O.; de Niet, A.; Tielliu, I.F.J.; Schurink, G.W.H.; Zeebregts, C.J. Outcome of Fenestrated Endovascular Aneurysm Repair in Octogenarians: A Retrospective Multicentre Analysis. Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. **2020**, *59*, 24–30. [CrossRef]
17. Prendes, C.F.; Spath, P.; Khashram, M.; Dias, N.; Furlan, F.; Gouveia E Melo, R.; Gallitto, E.; Sonesson, B.; Mendes Pedro, L.; Gormley, S.; et al. International Collaborative Study Comparing Outcomes of Fenestrated Endovascular Aortic Repair in Octogenarian Versus Nonoctogenarian Patients: The FEVOC Study. Ann. Surg. **2025**, 282, 328–338. [CrossRef]

18. Locham, S.; Faateh, M.; Dakour-Aridi, H.; Nejim, B.; Malas, M. Octogenarians Undergoing Open Repair Have Higher Mortality Compared with Fenestrated Endovascular Repair of Intact Abdominal Aortic Aneurysms Involving the Visceral Vessels. Ann. Vasc. Surg. **2018**, 51, 192–199. [CrossRef]

19. Vaughan-Burleigh, S.; Leung, Y.Y.R.; Khan, F.; Lintott, P.; Howard, D.P.J. The Safety and Outcomes of Elective Endovascular Aneurysm Repair in the Elderly: A Systemic Review and Meta-Analysis. J. Endovasc. Ther. Off. J. Int. Soc. Endovasc. Spec. **2024**, 2024, 15266028241283669. [CrossRef]

20. Silveira, D.; Pitoulias, G.; Torsello, G.; Donas, K.P. Outcomes of Total Endovascular Treatment of Juxtarenal Aortic Aneurysms in Octogenarians. J. Vasc. Surg. **2016**, 63, 909–914. [CrossRef]

21. Elahwal, M.; Richards, T.; Imsirovic, A.; Bagga, R.; Almond, G.; Yusuf, S.W. Systematic Review of the Results of Fenestrated Endovascular Aortic Repair in Octogenarians. Ann. R. Coll. Surg. Engl. **2024**, 106, 106–117. [CrossRef] [PubMed]

22. AbuRahma, A.F.; Yacoub, M.; Mousa, A.Y.; Abu-Halimah, S.; Hass, S.M.; Kazil, J.; AbuRahma, Z.T.; Srivastava, M.; Dean, L.S.; Stone, P.A. Aortic Neck Anatomic Features and Predictors of Outcomes in Endovascular Repair of Abdominal Aortic Aneurysms Following vs. Not Following Instructions for Use. J. Am. Coll. Surg. **2016**, 222, 579–589. [CrossRef] [PubMed]

23. Charbonneau, P.; Hongku, K.; Herman, C.R.; Habib, M.; Girsowicz, E.; Doonan, R.J.; Dubois, L.; Hossain, S.; Gill, H.L.; Mackenzie, K.S.; et al. Long-Term Survival after Endovascular and Open Repair in Patients with Anatomy Outside Instructions for Use Criteria for Endovascular Aneurysm Repair. J. Vasc. Surg. **2019**, 70, 1823–1830. [CrossRef] [PubMed]

24. Tenorio, E.R.; Dias-Neto, M.F.; Lima, G.B.B.; Baghbani-Oskouei, A.; Oderich, G.S. Lessons Learned over 2 Decades of Fenestrated- Branched Endovascular Aortic Repair. Semin. Vasc. Surg. **2022**, 35, 236–244. [CrossRef]

25. Schanzer, A.; Oderich, G.S. Management of Abdominal Aortic Aneurysms. N. Engl. J. Med. **2021**, 385, 1690–1698. [CrossRef]

26. Hicks, C.W.; Obeid, T.; Arhuidese, I.; Qazi, U.; Malas, M.B. Abdominal Aortic Aneurysm Repair in Octogenarians Is Associated with Higher Mortality Compared with Nonoctogenarians. J. Vasc. Surg. **2016**, 64, 956–965.e1. [CrossRef]
27. Zil-E-Ali, A.; Aziz, F.; Medina, D.; Nejim, B.; Radtka, J.F. Fenestrated Endovascular Abdominal Aortic Aneurysm Repair in Octogenarians Is Associated with Higher Mortality and an Increased Incidence of Nonhome Discharge. J. Vasc. Surg. **2022**, 75, 1846–1854.e7.
[CrossRef]

28. Zil-E-Ali, A.; Paracha, A.W.; Alamarie, B.; Tall, A.; DeHaven, C.; Aziz, F. Systematic Review and Meta-Analysis to Assess Safety and Early Mortality in Octogenarians Undergoing Fenestrated and Branched Endovascular Aortic Repair for Complex Aortic Aneurysms. Ann. Vasc. Surg. **2025**, 114, 30–44. [CrossRef]

29. Tran, K.; Lee, A.M.; McFarland, G.E.; Sgroi, M.D.; Lee, J.T. Complex Endovascular Aneurysm Repair Is Associated with Higher Perioperative Mortality but Not Late Mortality Compared with Infrarenal Endovascular Aneurysm Repair among Octogenarians. J. Vasc. Surg. **2019**, 69, 327–333. [CrossRef]

30. Guéroult, A.M.; Bashir, A.; Azhar, B.; Budge, J.; Roy, I.; Loftus, I.; Holt, P. Long Term Outcomes and Durability of Fenestrated Endovascular Aneurysm Repair: A Meta-Analysis of Time to Event Data. Eur. J. Vasc. Endovasc. Surg. **2024**, 67, 119–129. [CrossRef]

31. Katsargyris, A.; de Marino, P.M.; Hasemaki, N.; Nagel, S.; Botos, B.; Wilhelm, M.; Verhoeven, E.L.G. Editor's Choice—Single Centre Midterm Experience with Primary Fenestrated Endovascular Aortic Aneurysm Repair for Short Neck, Juxtarenal, and Suprarenal Aneurysms. Eur. J. Vasc. Endovasc. Surg. **2023**, 66, 160–166. [CrossRef]

32. Nana, P.; Spanos, K.; Brotis, A.; Fabre, D.; Mastracci, T.; Haulon, S. Systematic Review on Early and Follow-up Mortality Rate in Octogenarians Treated with a Fenestrated and/or Branched Endovascular Aortic Repair. J. Endovasc. Ther. Off. J. Int. Soc. Endovasc. Spec. **2025**, 32, 567–577. [CrossRef]

33. Henebiens, M.; Vahl, A.; Koelemay, M.J.W. Elective Surgery of Abdominal Aortic Aneurysms in Octogenarians: A Systematic Review. J. Vasc. Surg. **2008**, 47, 676–681.
[CrossRef]

34. Rosenfeld, E.S.; Macsata, R.A.; Lala, S.; Lee, K.B.; Pomy, B.J.; Ricotta, J.J.; Sparks, A.D.; Amdur, R.L.; Sidawy, A.N.; Nguyen, B.-N. Open Surgical Repair of Juxtarenal Abdominal Aortic Aneurysms in the Elderly Is Not Associated with Increased Thirty-Day Mortality Compared with Fenestrated Endovascular Grafting. J. Vasc. Surg. **2021**, 73, 1139–1147.
[CrossRef] [PubMed]

35. Hofmann, A.G.; Leinweber, M.E.; Assadian, A.; Falkensammer, J.; Taher, F. The Effect of Age on Peri-Operative Outcomes after FEVAR. J. Clin. Med. **2023**, 12, 3858.
[CrossRef] [PubMed]

36. Vemuri, C.; Wainess, R.M.; Dimick, J.B.; Cowan, J.A.; Henke, P.K.; Stanley, J.C.; Upchurch, G.R. Effect of Increasing Patient Age on Complication Rates Following Intact Abdominal Aortic Aneurysm Repair in the United States. J. Surg. Res. **2004**, 118, 26–31.
[CrossRef] [PubMed]
37. Feridooni, T.; Gordon, L.; Mahmood, D.N.; Behdinan, A.; Eisenberg, N.; Crawford, S.; Lindsay, T.F.; Roche-Nagle, G. Age Is Not a Sole Predictor of Outcomes in Octogenarians Undergoing Complex Endovascular Aortic Repair. J. Vasc. Surg. **2024**, 80, 630–639.
[CrossRef]

38. Ainsworth, B.E.; Haskell, W.L.; Herrmann, S.D.; Meckes, N.; Bassett, D.R.; Tudor-Locke, C.; Greer, J.L.; Vezina, J.; Whitt-Glover, M.C.; Leon, A.S. 2011 Compendium of Physical Activities: A Second Update of Codes and MET Values. Med. Sci. Sports Exerc. **2011**, 43, 1575–1581.
[CrossRef]

39. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; C̈ elutkiene´, J.; Chioncel, O.; et al. 2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur. Heart J. **2023**, 44, 3627–3639.
[CrossRef]

40. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. **2024**, 105, S117–S314.
[CrossRef]

41. Khwaja, A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin. Pract. **2012**, 120, c179–c184.
[CrossRef]

42. Prouse, G.; Robaldo, A.; van den Berg, J.C.; Ettorre, L.; Mongelli, F.; Giovannacci, L. Impact of Multidisciplinary Team Meetings on Decision Making in Vascular Surgery: A Prospective Observational Study. Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. **2023**, 66, 130–135.
[CrossRef]